
Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets (OligoPhore TM / SemaPhore TM delivery platforms). The Company currently has two flagship siRNA programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-4... Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets (OligoPhore TM / SemaPhore TM delivery platforms). The Company currently has two flagship siRNA programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets. 더 보기
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.3 | 0.3 | 0.3 | 0 | 0 | CS |
4 | 0 | 0 | 0.3 | 0.3 | 0.3 | 0 | 0 | CS |
12 | -0.1972 | -39.6621078037 | 0.4972 | 0.575 | 0.3 | 31765 | 0.3945164 | CS |
26 | -0.6 | -66.6666666667 | 0.9 | 0.9384 | 0.3 | 71686 | 0.51695212 | CS |
52 | -1.5 | -83.3333333333 | 1.8 | 3.49 | 0.3 | 588825 | 1.79842088 | CS |
156 | -388.82 | -99.9229029605 | 389.12 | 860 | 0.3 | 2195899 | 56.75977731 | CS |
260 | -239.7 | -99.875 | 240 | 1548 | 0.3 | 1754738 | 183.46352744 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관